tecvayli
janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
teklistamab süstelahus
patheon manufacturing services llc - teklistamab - süstelahus - 90mg 1ml 1.7ml 1tk
teklistamab süstelahus
patheon manufacturing services llc - teklistamab - süstelahus - 10mg 1ml 3ml 1tk